Latest Revenue Growth News

Elixinol Wellness reported a 10.8% revenue increase in Q2 2025, supported by improved cash receipts and a focused cost containment program. The company secured new funding and launched a menopause-targeted product, positioning itself for margin growth and profitability in H2.

Weebit Nano reports solid progress in Q4 FY25 with key technology milestones and its first product design license, backed by a strong cash position.

Excite Technology Services has reported its highest-ever quarterly customer receipts of $6.3 million, driven by strong growth across its cybersecurity, digital forensics, and IT services divisions. The company also secured a significant $676,000 Federal Government contract and completed its NANGU Tactical Centre.

IMEXHS Limited reported steady Q2 FY25 revenue with an 11% rise in annual recurring revenue, supported by a $2.6 million capital raise and operational advances including a major Mexican contract win.

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

DigitalX Limited reported a 32.8% increase in digital asset holdings to $72.9 million and raised $20.7 million to pivot its treasury strategy firmly towards Bitcoin. The DigitalX Bitcoin ETF (BTXX) also surged, nearing $53 million in assets under management.

Activeport Group Ltd reported a strong Q4 FY25 with significant revenue growth in software and Network as a Service segments, underpinned by new contracts with leading telecom providers and improved cash flow management.

Energy Technologies Limited reported a modest revenue increase and significant cash outflow improvement in its latest quarterly update, while preparing strategic moves to manage liquidity.

Medical Developments International (MVP) reports positive operating cash flow in H2 FY25, driven by strong Penthrox sales and strategic distribution shifts in Europe. The company eyes further growth amid regulatory progress and efficiency gains.

IODM Limited reported a robust 37% increase in cash receipts for Q4 FY25, driven by strong UK education sector growth and new international revenue share agreements.

Resonance Health reports a solid quarter with key clinical trial milestones, expansion of trial sites, and multi-year Software-as-a-Medical Device contracts, underpinning a positive cashflow outlook.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.